My thinking exactly. This looks to be setting up like a future OTCBB to me. It has all of the characteristics (including the 4B SS) that could uplist it in short order as stem cells continue their march towards mainstream. In fact, I noticed that one of their PR comments about access to capital markets could be foreshadowing. JMO.